Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

5Total

Not Applicable (1)

P 1 (2)

P 2 (2)

Trial Status

Not Yet Recruiting2

Completed2

Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (5)

Showing 5 of 5 trials

NCT07686744Phase 1Not Yet Recruiting

Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma

NCT07379047Phase 2Recruiting

Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

NCT07361991Phase 1Not Yet Recruiting

IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer

NCT02069730Not ApplicableCompleted

A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

NCT01719744Phase 2CompletedPrimary

Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma

Showing all 5 trials

Advanced